Introduction Introduction Introduction Introduction
Pathological anxiety is one of most common mental disorders manifested by humans.
Anxiolytic substances, mostly belonging to the benzodiazepine group, occupy a prominent position in the ranking of drugs most utilized by man to minimize anxiety. Benzodiazepines enhance the activity of gama-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system (CNS), which results in its clinical effects, including anxiolysis, muscle relaxation, sedation and hypnosis (Kan et al., 1997; Uhlenhuth et al., 1999) . However, sedative and psychomotor deficits produced by benzodiazepine exposure are associated with an increased risk of motor vehicle accidents and hip fracture rates in the elderly, especially with longer acting compounds (Ray et al., 1989; Cummings and Klineberg, 1993; Hemmengarn et al., 1997; Barbone et al., 1998) .
Owing to the unfavorable risks produced by classical anxiolytics, the development of new effective but less potent to induce adverse reactions is necessary. Thus, considerable attention has been given to the plant-derived therapeutics by the scientific community and the pharmaceutical industry.
Acta Sci. Health Sci. Maringá, v. 27, n. 2, p. 145-150, 2005 Crude extracts of Valeriana officialis L. and Passiflora alata Dryander have been widely used since ancient times in many countries owing to their hypnotic, sedative and anxiolytic properties (Schultes, 1990; Carlini, 2003) .
Clinical and pre-clinical evidences have confirmed these therapeutic properties of the crude extracts of different species of the genus Valeriana and Passiflora, including Valeriana officialis L. and Passiflora alata Dryander (Leathwood et al., 1982; Andreatini and Leite, 1994; Houghton, 1999; Herrera-Arelano et al., 2001; Dhawan et al., 2001; Petry et al., 2001; De Paris et al., 2002; Andreatini et al., 2002) . Passiflora alata Dryander is known as maracuja-doce in Brazil and is the only species of the genus acknowledged, by the Brazilian Pharmacopeia (Vasconcelos and Cereda, 1994; Oliveira et al., 1994) .
The aim of the present study was to examine the anxiolytic and sedative effects of acute and repeated treatments employing a combined extract of Passiflora alata and Valeriana officinalis L. (EPV) in rats submitted to elevated plus-maze (EPM), a behavioral test for anxiolytic drugs. We also profiled the secondary pharmacologic activity for the combined extract of EPV on spontaneous locomotion in the open-field test, a behavioral model for sedative/stimulant drug (Royce, 1977) .
Material and methods
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A A A Animals nimals nimals nimals
Wistar male rats (50-55 days old, 220-250 g), 5 per cage, at constant room temperature (22-23°C), under a 12h light-dark cycle, with free access to food and water, were deployed. Procedures adopted were approved by the UEM Ethics Committee, and followed the norms recommended by international guiding principles for Biomedical Research Involving Animals (CIMS, Geneva, 1985) .
Preparation of the plant material Preparation of the plant material Preparation of the plant material Preparation of the plant material Each extract (Passiflora alata Dryander or Valeriana officialis L.) was produced separately and, after removal of the organic solvent, the remaining solid material was lyophilized. The phytotherapeutic compound (EPV) consisted of a combination of aqueous-ethanolic extracts from Passiflora alata Dryander leaves and Valeriana officinalis L. roots in a final composition of 65% ethanol with 9.3% dry residue. This combination standardizaton resulted in 0.02% valerenic acid and 0.13% flavonoids (apigenine).
Treatments Treatments Treatments Treatments
Treatment was performed only after the rats had been acclimatized to the above environment for at least 3 days. All experiments were carried out between 8:00 and 12:00 am. The dry residue (Herbarium Laboratório Botânico), was resuspended into sterile saline (0.9% NaCl) immediately before use. EPV and saline, as control, were administered orally by gavage. The acute and the repeated treatments were performed once daily, with sterile saline (control) or EPV solution containing doses of 5, 10 or 20 mg/kg, or acutely with EPV solution in doses of 150, 300 or 600 mg/kg, in a final volume of 2 mL/kg body weight. Diazepan (2 mg/kg), administered by intraperitoneal route (i.p.), was used as positive control to acute or a 15 day treatment. Diazepam was used directy from the ampoule in solution (União Química). Each rat was used once in EPM and 24-hours later in the OFT Experimental sessions were conducted 30min after acute or final treatment.
Elevated plus Elevated plus Elevated plus Elevated plus----maze test ( maze test ( maze test ( maze test (E E E EPM) PM) PM) PM)
The elevated plus-maze test procedure was performed according to original method (Pellow et al., 1986) 
The animals submitted to the same experimental conditions were placed in the OFT. During a 5min period, the number of squares visited (four feet placed in the same square) and rearing behavior were registered using Royce's validation criteria (Royce, 1977) .
Data Data Data Data ana ana ana analysis lysis lysis lysis
Data were expressed as mean ± S.E.M. for each group. A one-way analysis of variance (ANOVA), followed by Dunnett`s test for multiple comparisons, was used. Effects and differences were considered significant at p ≤ 0.05.
Results and discussion Results and discussion Results and discussion Results and discussion
In order to determine the effective dose of the combined extract of EPV on EPM in rats, increasing doses of the extract were tested after acute or repeated treatment (3, 7 or 15-days) by gavage. The combined extract of EPV at a dose of 20 mg/kg increased the percentage entries and time spent in Acta Sci. Health Sci. Maringá, v. 27, n. 2, p. 145-150, 2005 open arms in EPM, indicating anxiolytic-like effect only after a 15 day treatment. Only after acute administration the higher doses (300 or 600 mg/kg) of the combined extract of EPV produced a significant decrease in locomotor activity in the OFT, revealing sedative effect. Figure 1 shows that the acute treatment with plant extract at any doses had no significant effect on any of the parameters that were measured on the EPM. Significant treatment effect was detected in percentage entries (F 4,30 = 9.566, P < 0.0001) (upper panel) Table 1 shows that locomotor activity, analyzed by the number of crossings in the OFT was not statistically affected by EPV at doses 5, 10 or 20 mg/kg or diazepam, after acute (F4,29 = 1.066, p = 0.3910) or 15 day repeated (F4,30 = 1.842, p = 0.1468) treatment. However: ambulation was decreased after acute treatment with doses of 300.0 (p < 0.05), and 600.0 mgPV/kg (p < 0.01) treatment, indicating a significant sedative effect (F4,30 = 12.33, p = 0.0001) compared to the respective control groups.
Results show that a 15 day repeated treatment with 20.0 mg/kg combined EPV extract produced anxiolytic effect, as measure in the EPM. The same EPV dose 15 administered during 15 days did not alter locomotor activity in OFT, indicating a lack of sedative or stimulant effect.
Behavior in EPM is apparently driven by the conflict between fear (open space and novelty) and exploration (novelty). (Pellow et al., 1986) . (C, saline, v.o.) in the OFT (n = 6-8). Statistically significant from the respective control group at p < 0.05* and p < 0.01**.
Due to changes in locomotor activity may also influence exploratory behavior in EPM, ambulatory behavior, evaluated by the number of crossings of squares in OFT, has been used to quantify this factor. OFT is an experimental rodent model specifically employed for the study of locomotor activity (Wash and Cummins, 1976; Royce, 1977) .
The effects of benzodiazepine drugs, which include clinical effects, like anxiolysis, have been detected after acute administration, and involve enhancement of GABA activity. Although relatively safe, these drugs can produce adverse effects, including decreased psychomotor activity and memory impairment (Longo and Johnson, 2000) .
In the present study we demonstrated that the EPV extract affects locomotor activity only when administered at doses much higher than those eliciting anxiolytic effects. Thus, the acute administration of higher EPV doses produced no significant, dose-dependent decrease in the parameters analyzed in the EPM that might reflect tendency to anxiogenic or sedative effects. The significant decrease of the crossings numbers detected using 300 or 600 mg EPV/kg in the OFT, indicates sedative effect.
Clinical studies show a significant improvement in sleep quality in patients using Valeriana officialis extracts (Leathwood et al., 1982; Leathwood and Chauffard, 1985; ) . Different constituents of Valeriana officialis may interact with the GABA system in the brain, which may explain its anxiolytic and sedative/hypnotic effects (Morazzoni and Bombardelli, 1995) .
Other studies have reported anxiolytic effect for an aqueous extract of Passiflora alata Dryander, but the active principles responsible for these effects have not yet been identified (Petry et al., 2001; De Paris et al., 2002; Carlini, 2003) . Acta Sci. Health Sci. Maringá, v. 27, n. 2, p. 145-150, 2005 The benzodiazepine receptor antagonist flumazenil failed to block the anxiolytic/sedative activities and nootropic effect of a standardized extract of Passiflora incarnata, suggesting that these effects are not mediated by action on benzodiazepine/GABA receptors (Soleimani et al., 1997 , Slomp Jr, 2004 .
In our study the anxiolytic effect was detected after repeated, but not after acute PV administration. This suggests that combined extract may act through a different mechanism Than that of benzodiazepine drugs.
Some antidepressant drugs which act on serotoninergic transmission are also effective anxiolytic agents (Ballenger, 1993; Argyropoulos et al., 2000) . However, the effectiveness in treating anxiety disorders of the different anti-depressant drugs has been observed only after chronic administration (Teixeira et al., 2000; Poltronieri et al., 2003) .
Current results demonstrate anxiolytic and sedative effects of the combined extracts of Passiflora alata Dryander and Valeriana officinalis L., which may be of relevance to the treatment of anxiety and insomnia. The anxiolytic effect was detected in doses 15 times less than that required to produce a sedative effect, revealing a wide dose range for the anxiolytic effect of the compound, and a lower potential to induce adverse sedative effects than benzodiazepines.
